Target intelligence / Profile preview

Crystallin beta B1 (CRYBB1)

Target
CRYBB1
Molecular classification
Structural protein, Crystallin family (specifically, the β-crystallin group, basic subclass), Beta/gamma-crystallin superfamily, Not classified as receptor, enzyme, transporter, ion channel, or transcription factor
01

Overview

Crystallin beta B1 is a structural protein that represents one of the primary components of the vertebrate eye lens, encoded by the CRYBB1 gene. It belongs to the beta-crystallin family, which forms oligomeric complexes essential for lens transparency and refractive function. Beta B1 crystallin is especially notable for its role in forming higher-order protein assemblies through homo- and hetero-oligomerization with other beta-crystallins. The protein undergoes age-related and maturation-related truncations, and mutations or misfolding can lead to the formation of protein aggregates and cataracts, which are a major cause of reduced vision. Unlike receptor or enzyme targets, crystallin beta B1 is not an active molecule in signaling or metabolism, but changes in its structural integrity have direct clinical consequences for lens health. There are currently no known drugs that act directly upon it.

Other names
Beta-crystallin B1CRYBB1 (gene symbol)Beta B1 crystallinCrystallin, beta B1
02

Mechanism of action

Not applicable. Since there are no drugs that modulate Crystallin beta B1 directly, mechanism of action is not defined

03

Biological functions

Structural constituent of eye lensMaintenance of lens transparency and refractive indexAssembly into homo- and hetero-oligomers for higher-order organization in the lens
04

Disease associations

Cataract (congenital and age-related cataracts)No direct role in cancer, inflammation, infection, neurodegeneration, or cardiovascular disease
05

Safety considerations

Protein instability and aggregation: Age-related truncation or mutation can cause loss of solubility, aggregation, and light scattering in the lens, leading to cataract formationStructural lifetime requirement: The protein must remain stable for the life of the lens fiber cell due to the absence of macromolecular synthesis or degradation machinery in these cells
06

Interacting drugs

None known. There are no approved drugs or pharmacological agents known to directly target Crystallin beta B1 as its dysfunction is structural, not regulatory or catalytic in nature
07

Biomarkers

Mutations or truncations in CRYBB1 are biomarkers for specific congenital and age-related cataract phenotypes (e.g., Cataract 17, Cataract 30)

Beyond the preview

Go deeper on Crystallin beta B1 (CRYBB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crystallin beta B1 (CRYBB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call